Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Deering

Pain Medicine Charlotte, NC Medical Doctor

NPI 1043576051 CMS profile 2537916

7825 Ballantyne Commons Pkwy Ste 150, Charlotte, NC 28277

Open in the dashboard

General payments

$93,078

537 records reported · program years 2019–2025

Research payments

$150

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Deering of Charlotte, NC is reported in the CMS Open Payments database as having received $93,078 across 537 general payments and $150 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,522 97
2024 General $25,176 79
2023 General $6,307 79
2022 General $6,678 69
2021 General $4,684 87
2020 General $3,740 76
2019 General $10,972 50
2019 Research $150 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Deering
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to James Deering were reported at $35,522. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year James Deering Pain Medicine median Middle half National median
2019 $10,972 $506 $144–$1,566 $163
2020 $3,740 $315 $96–$934 $114
2021 $4,684 $452 $134–$1,237 $132
2022 $6,678 $475 $124–$1,407 $149
2023 $6,307 $480 $136–$1,384 $160
2024 $25,176 $521 $164–$1,511 $164
2025 $35,522 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $56,698 241 payments
  2. Nevro Corp. $12,312 117 payments
  3. Saluda Medical Americas, Inc. $10,028 48 payments
  4. Medtronic USA, Inc. $8,676 22 payments
  5. Medtronic, Inc. $1,658 23 payments
  6. Relievant Medsystems, Inc. $1,169 15 payments
  7. Abbott Laboratories $657 5 payments
  8. Painteq LLC $478 9 payments
  9. Vertos Medical, Inc. $252 6 payments
  10. Biodelivery Sciences International, Inc. $183 12 payments
  11. Other $968 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,413 25 payments
  2. Food and Beverage $21,355 447 payments
  3. Travel and Lodging $12,585 56 payments
  4. Grant $7,500 1 payment
  5. Consulting Fee $5,400 5 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $3,825 3 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $35,681 150 payments
  2. SYNCHROMED $7,516 3 payments
  3. Evoke $6,719 26 payments
  4. Omnia $5,867 32 payments
  5. Senza Spinal Cord Stimulation System $4,974 61 payments
  6. Evoke SCS $3,309 22 payments
  7. WAVEWRITER ALPHA $1,417 10 payments
  8. Senza $1,321 22 payments
  9. INCEPTIV $1,279 16 payments
  10. Intracept $797 8 payments
  11. Other $8,630 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $150 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

401

Median for Interventional Pain Management: 1,220

Drug cost

$6,568

Median for Interventional Pain Management: $39,344

Branded share of claims

21.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 29 $1,641
Celecoxib Generic 30 $1,378
Gabapentin Generic 90 $1,034
Diclofenac Sodium Generic 20 $663
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 57 $590
Tramadol Hcl Generic 64 $478
Pregabalin Generic 24 $342
Cyclobenzaprine Hcl Generic 15 $202
Meloxicam Generic 32 $91
Tizanidine Hcl Generic 15 $90

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$93,786

Medicare's payments for the services billed

Medicare patients

275

Average age 74

Services billed

1,171

169 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 28%
Diabetes 24%
Chronic kidney disease 24%
Ischemic heart disease 23%
Cancer 21%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

538 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record